2.11
price up icon1.93%   0.04
 
loading
Biocardia Inc stock is traded at $2.11, with a volume of 70,635. It is up +1.93% in the last 24 hours and down -12.81% over the past month. BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
70,635
Relative Volume:
0.88
Market Cap:
$10.93M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.2993
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
+12.23%
1M Performance:
-12.81%
6M Performance:
-10.21%
1Y Performance:
-59.81%
1-Day Range:
Value
$1.99
$2.14
1-Week Range:
Value
$1.80
$2.14
52-Week Range:
Value
$1.625
$5.69

Biocardia Inc Stock (BCDA) Company Profile

Name
Name
Biocardia Inc
Name
Phone
650-226-0123
Name
Address
320 SOQUEL WAY, SUNNYVALE, CA
Name
Employee
17
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
BCDA's Discussions on Twitter

Compare BCDA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
0.41 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.06 372.90M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
10.42 211.65M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
2.81 122.73M 0 0 0 0.00
 icon
MOBBW
Mobilicom Limited Warrants
0.4785 397.07M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1609 340.19M 2.07B -1.42B -1.37B -0.6765

Biocardia Inc Stock (BCDA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-16-21 Downgrade Dawson James Buy → Neutral

Biocardia Inc Stock (BCDA) Latest News

pulisher
May 21, 2025

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus

May 21, 2025
pulisher
May 21, 2025

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - The Manila Times

May 21, 2025
pulisher
May 21, 2025

BioCardia Reveals Latest Progress on Revolutionary Cell Therapy for Heart Failure at Major Healthcare Conference - Stock Titan

May 21, 2025
pulisher
May 16, 2025

BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025
pulisher
May 15, 2025

BioCardia’s Earnings Call: Progress Amid Financial Strain - TipRanks

May 15, 2025
pulisher
May 15, 2025

BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

BioCardia Reports Positive Q1 2025 Progress - TipRanks

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: BioCardia’s Q1 2025 results show clinical progress - Investing.com

May 14, 2025
pulisher
May 14, 2025

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times

May 14, 2025
pulisher
May 14, 2025

BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan

May 14, 2025
pulisher
May 10, 2025

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - The Manila Times

May 10, 2025
pulisher
May 10, 2025

BioCardia to Host Q1 2025 Corporate Update and Financial Results - GuruFocus

May 10, 2025
pulisher
May 06, 2025

BioCardia (BCDA) Expands Enrollment for Phase 3 CardiAMP HF II T - GuruFocus

May 06, 2025
pulisher
May 06, 2025

BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks

May 06, 2025
pulisher
May 06, 2025

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - The Manila Times

May 06, 2025
pulisher
May 02, 2025

First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo

May 02, 2025
pulisher
May 02, 2025

Form 8-KCurrent report - ADVFN

May 02, 2025
pulisher
May 01, 2025

BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq

May 01, 2025
pulisher
May 01, 2025

BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BioCardia Enrolls First Patient in Phase III Trial - TipRanks

May 01, 2025
pulisher
May 01, 2025

BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan

May 01, 2025
pulisher
May 01, 2025

BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus

May 01, 2025
pulisher
Apr 26, 2025

Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Australia

Apr 26, 2025
pulisher
Apr 25, 2025

Biocardia CFO David McClung buys $24,999 in company stock - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

BioCardia Executives Increase Their Stakes in the Company - TradingView

Apr 25, 2025
pulisher
Apr 22, 2025

Biocardia CEO Peter Altman acquires $1,488 in stock - MSN

Apr 22, 2025
pulisher
Apr 21, 2025

Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com

Apr 21, 2025
pulisher
Apr 20, 2025

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN

Apr 20, 2025
pulisher
Apr 18, 2025

Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa

Apr 18, 2025
pulisher
Apr 17, 2025

Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 16, 2025

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo

Apr 16, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times

Apr 15, 2025
pulisher
Apr 15, 2025

Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia

Apr 14, 2025

Biocardia Inc Stock (BCDA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Biocardia Inc Stock (BCDA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Altman Peter
President and CEO
May 22 '25
Buy
1.89
700
1,323
141,666
Altman Peter
President and CEO
May 16 '25
Buy
2.43
300
730
139,366
Altman Peter
President and CEO
May 14 '25
Buy
2.99
100
299
139,066
KRASNO RICHARD M
Director
Apr 23 '25
Buy
1.91
13,123
24,999
16,268
McClung David
Chief Financial Officer
Apr 23 '25
Buy
1.91
13,123
24,999
43,131
Facteau Bill
Director
Apr 23 '25
Buy
1.91
13,123
24,999
13,123
Blank Andrew Scott
Director
Apr 23 '25
Buy
1.91
131,233
249,999
265,957
STERTZER SIMON H
Director
Apr 23 '25
Buy
1.91
104,986
199,998
120,365
Altman Peter
President and CEO
Apr 23 '25
Buy
1.91
26,246
49,999
138,966
Altman Peter
President and CEO
Apr 15 '25
Buy
2.14
100
214
112,720
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$285.56
price down icon 1.56%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Cap:     |  Volume (24h):